Self-reported signs of lipodystrophy by persons living with HIV infection

International Journal of STD and AIDS

Volumn 13, Issue 6, 2002, Pages 393-398

  Dreezen, C ^a   Schrooten, W ^a   De Mey, I ^a   Goebel, F D ^b   Dedes, N ^c   Florence, E ^a   Colebunders, R ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Centre for Inspirational Living   (Greece)

Author keywords

HIV infection; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ABDOMINAL DISEASE; ADULT; ARTICLE; BREAST DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EUROPE; FEMALE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; PREVALENCE; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; SELF DISCLOSURE;

EID: 0036273989     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646202760029813     Document Type: Article

References (25)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Indinavir-associated lipodystrophy
3. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
4. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
5. HIV PIs block adipogenesis and increase lipolysis in vitro
6. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
7. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
8. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
9. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
10. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
11. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
12. Adverse effects of antiretroviral therapy
13. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database
14. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999
15. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
16. Risk of lipodystrophy in HIV infected patients treated with protease inhibitors: A prospective cohort study
17. Stavudine versus zidovudine and the development of lipodystrophy
18. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
19. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
20. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine